2 December 2019 - The EMA and the US FDA have committed to engaging patients in their regulatory processes to promote patient-focused medicinal product development, as well as improve transparency and trust in the regulatory system. 

Here, we highlight exchanges of experience between the agencies and some impacts on patient engagement.

Read Nature Reviews Drug Discovery article